Member Info for gtc1507

Revenues in line with market expectations.

Great the order book showing clear recovery with revenues banked already significantly up on the h1 figure

February brokers note predicting 1.115m revenue for this year will be interesting to see if they’ve managed to close other stuff off in past weeks of the year. They’ve certainly done a good job banking contracts to materialise in 24/25 so should see a boost there!

Me too! Crazy price too good not to

They only raised 2 months ago and have cash runway into FY26……think you need to do your research

What you anticipating and when?

Lol you were right last time Chris but would love to know where your source gets this from!!

Also I wouldn’t trust accuracy of LinkedIn too much! Just because someone is a senior scientist doesn’t mean there is a junior below them always. Could be recognition of the skill and calibre of expertise required for complex technical roles. Also the company has restructured and we don’t know what the reporting lines are like now.

They’re pretty bad at communication and have said themselves they won’t announce every contract they get so hopefully we see the momentum in their trading update

I suspect no news this week and a wide ranging trading update next week after their April Board meeting.

Some marketing of MD going out

https://www.linkedin.com/posts/fusion-antibodies-plc_fusion-antibodies-mammalian-display-activity-7188501312152494080-1KbS?utm_source=share&utm_medium=member_ios

Is this the week for a big move? Trading update? NCI update? Would be great to hear!

Look at the detail of it - responsible for the commercialisation of Optimal and Mammalian Display. The NCI validation must be going well if they’re pushing the go button on roles for commercialisation

That’s very reasonable for a principal. Northern Ireland cost base is low currently but good supply of skilled labour

What’s the NCI event link?

Their LinkedIn page suggests a couple of staff have been rehired. Regardless, it’s quite positive to see that staff want to return to the company after being made redundant. Suggests a good culture and if it was me I wouldn’t want to go back unless they were confident they won’t be in a similar position as before and they had faith in the position of the business!

Https://www.linkedin.com/posts/fusion-antibodies-plc_optiphage-antibodydiscovery-antibodies-activity-7186342183057166336-OvFX?utm_source=share&utm_medium=member_ios

They’re not taking contracts with zero revenue - they clearly stated they will receive fees for their services on that RNS yesterday, just that they’re not material. This has been clear from start that Optiphage is a lower price point service - they’ve been clever here in that they’ve managed to secure long stream revenue potential from a more attractive lower price service as part of diversification, which is evidently working.

Where did you see that enable significant cash flow from royalty’s line Chris?

Truly baffling response to this great news!!

Totally agree - this is nuts response from market. Large player in diagnostics sector - potential to see returns much quicker than if this was clinical antibody too as they’ll not need to go through trials etc! Only can be seen as positive!

“ a leading global provider of antibodies for use in research and diagnostics ”